MSH Capital Advisors LLC Acquires 106 Shares of Johnson & Johnson (NYSE:JNJ)

MSH Capital Advisors LLC lifted its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 0.7% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 14,989 shares of the company’s stock after acquiring an additional 106 shares during the period. MSH Capital Advisors LLC’s holdings in Johnson & Johnson were worth $2,486,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Highline Wealth Partners LLC grew its position in Johnson & Johnson by 51.8% in the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock worth $42,000 after purchasing an additional 86 shares in the last quarter. Stone House Investment Management LLC bought a new position in shares of Johnson & Johnson during the 1st quarter valued at approximately $47,000. von Borstel & Associates Inc. bought a new position in shares of Johnson & Johnson during the 1st quarter valued at approximately $49,000. Capital A Wealth Management LLC bought a new position in shares of Johnson & Johnson during the 4th quarter valued at approximately $50,000. Finally, Harvest Fund Management Co. Ltd bought a new position in shares of Johnson & Johnson during the 1st quarter valued at approximately $52,000. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Stock Performance

Johnson & Johnson stock opened at $172.79 on Wednesday. The firm’s fifty day moving average price is $160.00 and its 200-day moving average price is $157.90. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. The stock has a market cap of $416.14 billion, a P/E ratio of 18.48, a price-to-earnings-growth ratio of 2.21 and a beta of 0.41. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $174.76.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The firm had revenue of $23.74 billion for the quarter, compared to analysts’ expectations of $22.85 billion. During the same quarter last year, the company posted $2.82 EPS. The business’s quarterly revenue was up 5.8% on a year-over-year basis. On average, equities research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th will be issued a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, August 26th. This represents a $5.20 annualized dividend and a dividend yield of 3.0%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 55.61%.

Analyst Ratings Changes

A number of analysts recently commented on the stock. Morgan Stanley upped their price target on shares of Johnson & Johnson from $171.00 to $176.00 and gave the company an “equal weight” rating in a research note on Thursday, July 17th. Wall Street Zen cut shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research note on Friday, July 18th. Benchmark upgraded shares of Johnson & Johnson to a “strong-buy” rating in a research note on Thursday, April 24th. Sanford C. Bernstein restated a “market perform” rating on shares of Johnson & Johnson in a research note on Wednesday, April 16th. Finally, Erste Group Bank upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research note on Wednesday, July 23rd. Nine equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $174.50.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.